We are live on ! Find out more
TLC

Taiwan Liposome
TLC

Delisted

TLC was delisted on the 28th of September, 2021.

5 hedge funds and large institutions have $3.8M invested in Taiwan Liposome in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+5
Holders Change %
–
% of All Funds
0.11%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

TLC Hedge Fund Activity: Q4 2018 in Review

5 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Taiwan Liposome (TLC) for Q4 2018, worth a combined $3.8M.

Buyers outnumbered sellers: 5 funds opened new TLC positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Karst Peak Capital, opening a new position worth an estimated $3.38M.

  • 5 institutional investors held Taiwan Liposome (TLC) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $3.8M of Taiwan Liposome stock for Q4 2018.
  • 5 funds opened new Taiwan Liposome positions in Q4 2018 and 0 closed out, a net change of +5 holders.
  • The largest Taiwan Liposome buyer in Q4 2018 was Karst Peak Capital, an estimated $3.38M added.

Based on aggregated 13F filings for Q4 2018.